Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

represents a single or double bond, provided if a double bond is present, then one of R 6a or R 6b is absent;

R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR A1 , —N(R A1 ) 2 , —SR A1 , —C(═O)R A1 , —C(═O)OR A1 , —C(═O)SR A1 , —C(═O)N(R A1 ) 2 , —OC(═O)R A1 , —OC(═O)OR A1 , —OC(═O)N(R A1 ) 2 , —OC(═O)SR A1 , —OS(═O) 2 R A1 , —OS(═O) 2 OR A1 , —OS(═O) 2 N(R A1 ) 2 , —N(R A1 )C(═O)R A1 , —N(R A1 )C(═NR A1 )R A1 , —N(R A1 )C(═O)OR A1 , —N(R A1 )C(═O)N(R A1 ) 2 , —N(R A1 )C(═NR A1 )N(R A1 ) 2 , —N(R A1 )S(═O) 2 R A1 , —N(R A1 )S(═O) 2 OR A1 , —N(R A1 )S(═O) 2 N(R A1 ) 2 , —SC(═O)R A1 , —SC(═O)OR A1 , —SC(═O)SR A1 , —SC(═O)N(R A1 ) 2 , —S(═O) 2 R A1 , —S(═O) 2 OR A1 , or —S(═O) 2 N(R A1 ) 2 , wherein each R A1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two R A1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;

each of R 2a , R 2b , R 4a , R 4b , R 7a , R 7b , R 11a , R 11b , R 12a , R 12b , and R 17b , is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR A1 , —N(R A1 ) 2 , —SR A1 , —C(═O)R A1 , —C(═O)OR A1 , —C(═O)SR A1 , —C(═O)N(R A1 ) 2 , —OC(═O)R A1 , —OC(═O)OR A1 , —OC(═O)N(R A1 ) 2 , —OC(═O)SR A1 , —OS(═O) 2 R A1 , —OS(═O) 2 OR A1 , —OS(═O) 2 N(R A1 ) 2 , —N(R A1 )C(═O)R A1 , —N(R A1 )C(═NR A1 )R A1 , —N(R A1 )C(═O)OR A1 , —N(R A1 )C(═O)N(R A1 ) 2 , —N(R A1 )C(═NR A1 )N(R A1 ) 2 , —N(R A1 )S(═O) 2 R A1 , —N(R A1 )S(═O) 2 OR A1 , —N(R A1 )S(═O) 2 N(R A1 ) 2 , —SC(═O)R A1 , —SC(═O)OR A1 , —SC(═O)SR A1 , —SC(═O)N(R A1 ) 2 , —S(═O) 2 R A1 , —S(═O) 2 OR A1 , or —S(═O) 2 N(R A1 ) 2 , wherein each R A1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two R A1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;

R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 5 is hydrogen or methyl; when is a double bond, R 5 is absent;

each of R 6a and R 6b is hydrogen, halogen, —CN, —NO 2 , —OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; or R 6a and R 6b are joined to form an oxo (═O) group;

each of R 15a , R 15b , R 16a and R 16b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR C3 , —N(R C3 ) 2 , —SR C3 , —C(═O)R C3 , —C(═O)OR C3 , —C(═O)SR C3 , —C(═O)N(R C3 ) 2 , —OC(═O)R C3 , —OC(═O)OR C3 , —OC(═O)N(R C3 ) 2 , —OC(═O)SR C3 , —OS(═O) 2 R C3 , —OS(═O) 2 OR C3 , —OS(═O) 2 N(R C3 ) 2 , —N(R C3 )C(═O)R C3 , —N(R C3 )C(═NR C3 )R C3 , —N(R C3 )C(═O)OR C3 , —N(R C3 )C(═O)N(R C3 ) 2 , —N(R C3 )C(═NR C3 )N(R C3 ) 2 , —N(R C3 )S(═O) 2 R C3 , —N(R C3 )S(═O) 2 OR C3 , —N(R C3 )S(═O) 2 N(R C3 ) 2 , —SC(═O)R C3 , —SC(═O)OR C3 , —SC(═O)SR C3 , —SC(═O)N(R C3 ) 2 , —S(═O) 2 R C3 , —S(═O) 2 OR C3 , or —S(═O) 2 N(R C3 ) 2 , wherein each R C3 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two R C3 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;

R 19 is substituted or unsubstituted C3-C6 carbocyclyl or substituted or unsubstituted aryl; and

n is 0, 1 or 2.

2. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

3. The compound or pharmaceutically acceptable salt of claim 2 , wherein R 1 is hydrogen, unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

4. The compound or pharmaceutically acceptable salt of claim 3 , wherein R 1 is selected from the group consisting of:

wherein:

each R a is independently hydrogen, halogen, —NO 2 , —CN, —OR D4 , —N(R D4 ) 2 , —C(═O)R D4 , —C(═O)OR D4 , —C(═O)N(R D4 ) 2 , —OC(═O)R D4 , —OC(═O)OR D4 , —N(R D4 )C(═O)R D4 , —OC(═O)N(R D4 ) 2 , —N(R D4 )C(═O)OR D4 , —S(═O) 2 R D4 , —S(═O) 2 OR D4 , —OS(═O) 2 R D4 , —S(═O) 2 N(R D4 ) 2 , or —N(R D4 )S(═O) 2 R D4 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl;

each R D4 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, or two R D4 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring; and

p is an integer selected from 0 to 11.

5. The compound or pharmaceutically acceptable salt of claim 1 , wherein each of R 2a and R 2b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, —OR E5 , —OC(═O)R E5 , —OS(═O) 2 OR E5 , —N(R E5 ) 2 , or —N(R E5 )C(═O)R E5 , —N(R E5 )S(═O) 2 R E5 , —N(R E5 )S(═O) 2 OR E5 ; wherein each R E5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R E5 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring.

6. The compound or pharmaceutically acceptable salt of claim 5 , wherein each of R 2a and R 2b is independently hydrogen, —OH, substituted or unsubstituted |C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.

7. The compound or pharmaceutically acceptable salt of claim 6 , wherein each of R 2a and R 2b is independently hydrogen, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —CH(CH 3 ) 2 .

8. The compound or pharmaceutically acceptable salt of claim 7 , wherein R 2a and R 2b are both hydrogen.

9. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.

10. The compound or pharmaceutically acceptable salt of claim 9 , wherein R 3a is substituted or unsubstituted C 1-6 alkyl.

11. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 3a is hydrogen, methyl, methoxymethyl, or ethoxymethyl.

12. The compound or pharmaceutically acceptable salt of claim 1 , wherein each of R 4a and R 4b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, —OR E5 , —OC(═O)R E5 , —OS(═O) 2 OR E5 , —N(R E5 ) 2 , —N(R E5 )C(═O)R E5 , —N(R E5 )S(═O) 2 R E5 , or —N(R E5 )S(═O) 2 OR E5 ; wherein each R E5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R E5 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring.

13. The compound or pharmaceutically acceptable salt of claim 12 , wherein each of R 4a and R 4b is independently hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.

14. The compound or pharmaceutically acceptable salt of claim 13 , wherein each of R 4a and R 4b is independently hydrogen, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —CH(CH 3 ) 2 .

15. The compound or pharmaceutically acceptable salt of claim 14 , wherein R 4a and R 4b are both hydrogen.

16. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 5 is hydrogen or methyl in the cis position, relative to R 19 .

17. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 5 is hydrogen or methyl in the trans position, relative to R 19 .

18. The compound or pharmaceutically acceptable of claim 1 , wherein each of R 6a and R 6b is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.

19. The compound or pharmaceutically acceptable salt of claim 18 , wherein each of R 6a and R 6b is independently hydrogen or unsubstituted alkyl.

20. The compound or pharmaceutically acceptable salt of claim 19 , wherein both R 6a and R 6b are hydrogen.

21. The compound or pharmaceutically acceptable salt of claim 1 , wherein each of R 7a and R 7b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, —OR E5 , —OC(═O)R E5 , —OS(═O) 2 OR E5 , —N(R E5 ) 2 , —N(R E5 )C(═O)R E5 , —N(R E5 )S(═O) 2 R E5 , or —N(R E5 )S(═O) 2 OR E5 ; wherein each R E5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R E5 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring.

22. The compound or pharmaceutically acceptable salt of claim 21 , wherein each of R 7a and R 7b is independently hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.

23. The compound or pharmaceutically acceptable salt of claim 22 , wherein each of R 7a and R 7b is independently hydrogen, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —CH(CH 3 ) 2 .

24. The compound or pharmaceutically acceptable salt of claim 23 , wherein R 7a and R 7b are both hydrogen.

25. The compound or pharmaceutically acceptable salt of claim 1 , wherein each of R 11a and R 11b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, —OR E5 , —OC(═O)R E5 , —OS(═O) 2 OR E5 , —N(R E5 ) 2 , —N(R E5 )C(═O)R E5 , —N(R E5 )S(═O) 2 R E5 , or —N(R E5 )S(═O) 2 OR E5 ; wherein each R E5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R E5 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring.

26. The compound or pharmaceutically acceptable salt of claim 25 , wherein each of R 11a and R 11b is independently hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.

27. The compound or pharmaceutically acceptable salt of claim 26 , wherein each of R 11a and R 11b is independently hydrogen, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —CH(CH 3 ) 2 .

28. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 11a and R 11b are both hydrogen.

29. The compound or pharmaceutically acceptable salt of claim 1 , wherein each of R 12a and R 12b is independently hydrogen, halogen, —CN, —NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, —OR E5 , —OC(═O)R E5 , —OS(═O) 2 OR E5 , —N(R E5 ) 2 , —N(R E5 )C(═O)R E5 , —N(R E5 )S(═O) 2 R E5 , or —N(R E5 )S(═O) 2 OR E5 ; wherein each R E5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R E5 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring.

30. The compound or pharmaceutically acceptable salt of claim 29 , wherein each of R 12a and R 12b is independently hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.

31. The compound or pharmaceutically acceptable salt of claim 30 , wherein each of R 12a and R 12b is independently hydrogen, —CH 3 , —CH 2 CH 3 , —OH, —OCH 3 , or —CH(CH 3 ) 2 .

32. The compound or pharmaceutically acceptable salt of claim 31 , wherein R 12a and R 12b are both hydrogen.

33. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 17b is fluorine, hydroxyl, methyl, or hydrogen; wherein the hydrogen is optionally replaced with deuterium.

34. The compound or pharmaceutically acceptable salt of claim 1 , wherein IV is substituted or unsubstituted C 3-6 carbocyclyl, or substituted or unsubstituted C 6-10 aryl.

35. The compound or pharmaceutically acceptable salt of claim 34 , wherein R 19 is selected from the group consisting of:

wherein:

each R b is, independently hydrogen, halogen, —NO 2 , —CN, —OR G7 , —N(R G7 ) 2 , —C(═O)R G7 , —C(═O)OR G7 , —C(═O)N(R G7 ) 2 , —OC(═O)R G7 , —OC(═O)OR G7 , —N(R G7 )C(═O)R G7 , —OC(═O)N(R G7 ) 2 , —N(R G7 )C(═O)OR G7 , —S(═O) 2 R G7 , —S(═O) 2 OR G7 , —OS(═O) 2 R G7 , —S(═O) 2 N(R G7 ) 2 , or —N(R G7 )S(═O) 2 R G7 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl;

each R G7 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, or two R G7 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring; and

q is an integer selected from 0 to 11.

36. The compound or pharmaceutically acceptable salt of claim 35 , wherein n is 0.

37. The compound or pharmaceutically acceptable salt of claim 35 , wherein n is 1.

38. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-a), (I-b), or (I-c):

or a pharmaceutically acceptable salt of any of these compounds.

39. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-d):

or a pharmaceutically acceptable salt thereof;

wherein:

each R a is independently halogen, cyano, hydroxyl, or substituted or unsubstituted alkyl; and

p is 0, 1, 2 or 3.

40. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-e):

or a pharmaceutically acceptable salt thereof;

wherein:

each X is independently —C(R N )—, —C(R N ) 2 —, —O—, —S—, —N—, or —N(R N )—; each R N is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, —C(═O)R GA , —C(═O)OR GA , —C(═O)N(R GA ) 2 , —S(═O) 2 R GA , or —S(═O) 2 N(R GA ) 2 ; and each R GA is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R GA groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring.

41. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-f):

or a pharmaceutically acceptable salt thereof;

wherein:

each X is independently —C(R N )—, —C(R N ) 2 —, —O—, —S—, —N—, or —N(R N )—; each R N is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, —C(═O)R GA , —C(═O)OR GA , —C(═O)N(R GA ) 2 , —S(═O) 2 R GA , or —S(═O) 2 N(R GA ) 2 ; and each R GA is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R GA groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring.

42. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-g):

or a pharmaceutically acceptable salt thereof;

wherein:

each R a is independently halogen, alkyl, hydroxyl, or cyano; and

p is an integer selected from 0 to 11.

43. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-h):

or a pharmaceutically acceptable salt thereof;

wherein:

each X is independently —C(R N )—, —C(R N ) 2 —, —O—, —S—, —N—, or —N(R N )—; each R N is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, —C(═O)R GA , —C(═O)OR GA , —C(═O)N(R GA ) 2 , —S(═O) 2 R GA , or —S(═O) 2 N(R GA ) 2 ; and each R GA is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocylyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R GA groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring.

44. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

45. A compound selected from

or a pharmaceutically acceptable salt thereof.

46. A pharmaceutical composition comprising a compound of claim 45 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.